AFC-HD AMS Life Science Co. Ltd. (2927.TO) | ||
Japan | ||
Half-Year Ended February 28 | ||
GROUP | 2025 | 2024 |
Revenue | Y16.61 bln | Y14.54 bln |
Operating Profit | Y1.29 bln | Y1.02 bln |
Pretax Profit | Y1.33 bln | Y1.06 bln |
Net Profit | Y881.00 mln | Y641.00 mln |
Per share | ||
Earnings | Y62.65 | Y45.79 |
Diluted Earnings | Y62.64 | Y45.74 |
Results are based on Japanese accounting standards. |
(END) Dow Jones Newswires
AFC-HD AMS Life Science Co. Ltd. also released the following forecasts: | |
GROUP | Year Ending |
Aug 2025 | |
Revenue | Y31.10 bln |
Operating Profit | Y2.20 bln |
Pretax Profit | Y2.20 bln |
Net Profit | Y1.32 bln |
Per share | |
Earnings | Y93.78 |
Results are based on Japanese accounting standards. |
This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.
(END) Dow Jones Newswires
April 14, 2025 02:36 ET (06:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。